Developing Antitussive Alternatives To DXM Would Offset Commercial Risk
This article was originally published in The Tan Sheet
Executive Summary
Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk
You may also be interested in...
New Products In Brief
Chloraseptic pops out line extensions
GSK Consumer Vet Scheske Sees OTC Potential In Biotech PepTcell's Portfolio
PepTcell is in the late stages of developing a potential blockbuster cough suppressant, says Manfred Scheske, head of the U.K. biotech's consumer business
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
Dextromethorphan likely will escape scheduling as a controlled substance in the near term, but manufacturers and lawmakers should push efforts to curb abuse to keep the cough suppressant available OTC in the long run